Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

THOUSAND OAKS, Calif., July 14, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN), in partnership with the International Federation of Psoriasis Associations (IFPA), announced the launch of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Innovation Challenge, a new global initiative that aims to make a big impact within the psoriatic disease community by fostering the development of actionable solutions to address a challenge that people living with psoriatic disease and healthcare providers continue to face.

Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge

Amgen is slightly undervalued today; it's a great value stock to keep on your radar. The company generates consistent free cash flows.

Amgen: Undervalued Stock For Your Radar

BeiGene

The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The approval covers Kyprolis in combination with dexamethasone for adult patients who have received at least two prior therapies, including a proteasome inhibitor and an immunomodulatory agent.

BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients

The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.

Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag

AstraZeneca

The FDA has accepted for review Amgen Inc's (NASDAQ: AMGN) marketing application seeking approval for tezepelumab to treat asthma.  Amgen is developing Tezepelumab in collaboration with AstraZeneca plc (NASDAQ: AZN).

Amgen - AstraZeneca's Asthma Candidate Under Priority Review With FDA

THOUSAND OAKS, Calif., July 7, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma.

Tezepelumab Granted Priority Review By U.S. FDA

AbbVie

Amazon

Alibaba

Gilead Sciences

General Mills

Alphabet

Henkel AG & Co KGaA

Reckitt Benckiser Group PLC

Tencent Holdings Limited

Walgreens

The stock market is overvalued, but we can still try to find investments without overpaying. A first category of stocks are recession-proof and undervalued companies like Walgreens Boots Alliance, Henkel, Amgen or AbbVie.

10 Picks For July

Enbridge

Polaris

Philip Morris

5 Amazing Blue-Chips That Could Soar 165% In 5 Years

Biogen

BioNTech SE

Moderna

Intellia Therapeutics

Regeneron Pharmaceuticals

Repligen

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

3 Biotech Stocks Poised to Gain in the Second Half of 2021

Amgen has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $20.37B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.83% yield

Why Amgen Is A Top 25 Dividend Giant

Broadcom

CMS Energy

Cisco Systems

Evergy Inc

Kellogg

Kimberly-Clark

Lockheed Martin

Alliant Energy

Merck

M&T Bank

PepsiCo

Principal Financial Group

Southern Company

Sempra Energy

Truist Financial

Vanguard High Dividend Yield ETF

WEC Energy Group

Xcel Energy

There are 20 High-Yield Dividend Stocks on the July 2021 watchlist. The watchlist lost 1.73% in June but is still up over 35% since November 2020.

High Yield Dividend Stocks For July 2021

Eli Lilly

Pfizer

We have been long-term owners of Amgen ( AMGN , Financial), Merck ( MRK , Financial) and Pfizer ( PFE , Financial) among the major pharma and biotech companies. We believe they trade at a ridiculous discount to similar companies in other industries.

Good Medicine at Bargain Prices

Amgen Inc (NASDAQ: AMGN) plans to build a $365 million pharmaceutical packaging facility in New Albany that will employ 400 workers.  The Ohio Tax Credit Authority Monday approved a state tax credit for the project.

Amgen Pumps $365M Into New Ohio Facility

The company is very stable and predictable.

Amgen: A Defensive Play In An Expensive Market

Colgate-Palmolive

Starbucks

T. Rowe Price Group

The ratio of return on invested capital (ROIC) compared to weighted average cost of capital (WACC) is an excellent way to determine which companies are best at maintaining and growing their profitability. The higher the ROIC, the more efficient the company is at turning invested dollars into profits.

4 Companies Delivering High Levels of Value Creation

THOUSAND OAKS, Calif., June 23, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig® (erenumab) for the suppression of onset of migraine attacks in adults.

Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults

REYKJAVIK, Iceland, June 18, 2021 /PRNewswire/ -- Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts  the time to all-cause  death better than traditional risk factors. In a paper published today in Communications Biology, scientists from deCODE genetics, a subsidiary of Amgen, describe how they developed  predictor of how much is left of the life of a person.

deCODE genetics: Predicting the probability of death

THOUSAND OAKS, Calif., June 15, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of being in his demanding role and dealing with a chronic skin condition.

Acclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis

Goldman Sachs

Amgen Inc. (AMGN) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

Legend Biotech

Sanofi

A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutting-edge treatments more quickly to Chinese patients.

Drug Startups Eye Quicker Profits Under China's New Fast-Track Approvals

Amgen Inc (NASDAQ: AMGN) presented data on overall survival from the Phase 2 results of the CodeBreaK 100 clinical study for Lumakras (sotorasib) in previously treated non-small-cell lung cancer (NSCLC) patients. Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine.

Amgen's Sotorasib is First KRAS Inhibitor to Show Overall Survival Benefit in Lung Cancer With KRAS Mutations

Amgen Inc.'s (AMGN) Management Presents at American Society of Clinical Oncology Annual Meeting Conference (Transcript)

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m.

Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for LUMAKRASTM (sotorasib) in previously treated patients with non-small cell lung cancer (NSCLC) during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial.

Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers

News for Amgen Stock (AMGN)